Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

OBJECTIVES: To evaluate safety and efficacy of weekly (qw) and every other week (q2w) dosing of sarilumab, a fully human anti-interleukin 6 receptor α (anti-IL-6Rα) monoclonal antibody, for moderate-to-severe rheumatoid arthritis (RA). METHODS: In this dose-ranging study, patients (n=306) with activ...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Huizinga, Tom W J, Fleischmann, Roy M, Jasson, Martine, Radin, Allen R, van Adelsberg, Janet, Fiore, Stefano, Huang, Xiaohong, Yancopoulos, George D, Stahl, Neil, Genovese, Mark C
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2014
Teme:
Clinical and Epidemiological Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4145418/
https://ncbi.nlm.nih.gov/pubmed/24297381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2013-204405
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items